Current location: Home > PRODUCTS > Real Time PCR Series Products

PRODUCTS

K-ras Gene Mutations Detection Kit


(CE-IVD/NMPA)



KRAS  MUTATIONS IN LUNG CANCER

Kirsten rat sarcoma viral oncogene (K-ras) is  the  most frequently mutated gene in patients with non-small cell lung cancer (NSCLC) in USA/Europe  and the second most frequently mutated gene in patients with NSCLC in East Asian, with a mutation frequency of 9.8%; about 30% of which are G12C mutations [1]. K-ras mutation is associated with poor prognosis (compared to wild type, HR=1.5, P=0.002) [1]. In May 2021, the FDA approved AMGEN's KRAS G12C inhibitor Sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy.



K-ras mutation and prognosis [1]



KRAS  MUTATIONS IN COLORECTAL CANCER

Cetuximab and panitumumab are monoclonal antibody drugs that target epidermal growth factor receptor (EGFR), which can competitively prevent EGFR from binding to its ligand and inhibit its downstream signal transmission. K-ras is located in the MAPK signaling pathway downstream of EGFR. The mutant K-ras protein does not depend on the regulation of EGFR, therefore,patients are resistant to cetuximab and panitumumab. The FDA specifically stated in the product instructions for cetuximab and Panitumumab that these drugs are not recommended for colorectal cancer patients with K-ras mutation.



DETECTED GENES

No.Mutation TypeBase ChangesNo.Mutation TypeBase Changes
1G12Dc.35G>A9

Q61

c.182A>T

2G12Ac.35G>C

Q61R

c.182A>G

3G12Vc.35G>T

Q61H

c.183A>C

4G12Sc.34G>A

Q61H

c.183A>T

5G12Rc.34G>C10

A59T

c.175G>A

6G12Cc.34G>T

Q61K

c.181C>A

7G13Dc.38G>A11

A146T

c.436G>A

8

G13Cc.37G>T

A146V

c.437C>T

G13Sc.37G>A

A146P

c.436G>C

G13Rc.37G>C


K117Nc.351A>C


K117Nc.351A>T



PRODUCT INFORMATION

Product Name

Core Technology

Pack SizeInstruments ValidatedSample Type

K-ras Gene Mutations

Detection Kit

PAP-ARMS®10 tests/kit

Stratagene Mx3000P™,

ABI7500 etc.

Tumor tissue,

Peripheral blood,

Pleural and ascites



DETECTION SIGNIFICANCE 

1. Select patients for treatment of locally advanced or metastatic NSCLC with G12C inhibitor based on the presence of KRAS G12C mutation in tumor or plasma specimens.

2. Patients with mutant KRAS gene show poor response to anti-EGFR or anti-HER2 therapies.




FEATURES & ADVANTAGES

1. Accuracy and Reliability: Use prer-load PCR tube to effectively avoid cross-contamination.

2. High Sensitivity: Sensitivity can reach as low as 1% in 10 ng DNA.

3. Ease of Use: Based on technology PAP-ARMS®, one step detection in 90 mins.

4. Great versatility:Validated on the most common qPCR machines with stable results.




DETECTION PROCESS 

1.Nucleic Acid Extraction

2.Set up qPCR

3.Amplification

4.Data Analysis



[1] Biomark Res. 2020 Jun 25;8:22.